Leerink Partners reissued their market perform rating on shares of Enhabit (NYSE:EHAB – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $8.00 price target on the stock, down from their prior price target of $8.50.
Enhabit Stock Performance
Enhabit stock opened at $7.56 on Tuesday. The stock has a market cap of $380.12 million, a P/E ratio of -3.28 and a beta of 1.84. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The stock has a 50 day moving average of $7.52 and a 200-day moving average of $8.41. Enhabit has a 52 week low of $6.85 and a 52 week high of $11.74.
Enhabit (NYSE:EHAB – Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to analysts’ expectations of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter last year, the company posted $0.03 earnings per share. On average, analysts expect that Enhabit will post 0.25 EPS for the current fiscal year.
Hedge Funds Weigh In On Enhabit
About Enhabit
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
- Five stocks we like better than Enhabit
- How to Effectively Use the MarketBeat Ratings Screener
- Tesla Investors Continue to Profit From the Trump Trade
- How to Use Stock Screeners to Find Stocks
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.